$XBI $71.46 | +4.38%
Table of Contents:
Covid Updates
$BNTX (+5.7%) & PFE(+1.3%) Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age source
Pipeline Updates
$CNTB +2.9% Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference source
$ADVM +2.3% Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022 source
$SRNE +9.0% Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) source
$SRNE +9.0% Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial). source
$IDRA +16.0% Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC. source
$HZNP +2.3% Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata. source
$ALZN +7.3% Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder. source
$CRDL +11.0% Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis. source
$CYTK -2.9% Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil. source
$ARVO +4.7% AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures. source
$NRIX +7.7% Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas. source
$INAB -11.4% IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform. source
$KALV +1.3% KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900. source
$CALT +3.8% First patient randomized in Phase 2 trial in head and neck cancer. source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$EVO (-2.9%) & $SVA Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes. source
$MNKD +9.8% MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma. source
Posted by FS/JM